Warm Springs Advisors Inc. Purchases New Shares in Thermo Fisher Scientific Inc. (NYSE:TMO)

Warm Springs Advisors Inc. acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 3,942 shares of the medical research company's stock, valued at approximately $2,051,000. Thermo Fisher Scientific comprises 1.9% of Warm Springs Advisors Inc.'s holdings, making the stock its 16th biggest position.

Several other large investors have also modified their holdings of TMO. Stonegate Investment Group LLC lifted its position in Thermo Fisher Scientific by 0.3% during the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock worth $3,531,000 after acquiring an additional 18 shares during the last quarter. Semus Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 4.0% during the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after purchasing an additional 18 shares during the period. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares during the period. Evernest Financial Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 4.0% in the 4th quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company's stock worth $271,000 after acquiring an additional 20 shares during the period. Finally, Proactive Wealth Strategies LLC grew its holdings in shares of Thermo Fisher Scientific by 2.7% during the 4th quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company's stock worth $392,000 after purchasing an additional 20 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Stifel Nicolaus dropped their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. UBS Group decreased their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Finally, Barclays cut their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $607.43.

Thermo Fisher Scientific Trading Up 0.5%

TMO traded up $2.04 during midday trading on Thursday, reaching $404.17. 1,296,850 shares of the company were exchanged, compared to its average volume of 2,315,475. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market capitalization of $152.57 billion, a P/E ratio of 24.45, a PEG ratio of 2.99 and a beta of 0.82. The stock's 50-day simple moving average is $435.42 and its 200 day simple moving average is $502.00. Thermo Fisher Scientific Inc. has a one year low of $390.49 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business's revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the business posted $5.11 earnings per share. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. The trade was a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,075 shares of company stock valued at $7,305,942. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.